Go Pro
→ Trump's gold order: the announcement they won't put on the front page (From Reagan Gold Group) (Ad)tc pixel
NASDAQ:PHVS

Pharvaris Q3 2025 Earnings Report

Pharvaris logo
$35.92 +1.33 (+3.85%)
Closing price 07/8/2026 04:00 PM Eastern
Extended Trading
$35.90 -0.02 (-0.07%)
As of 07/8/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Pharvaris EPS Results

Actual EPS
-$0.70
Consensus EPS
-$0.78
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A

Pharvaris Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pharvaris Announcement Details

Quarter
Q3 2025
Date
11/12/2025
Time
Before Market Opens
Conference Call Date
Tuesday, November 11, 2025
Conference Call Time
6:00PM ET

Upcoming Earnings

Pharvaris' Q2 2026 earnings is estimated for Tuesday, August 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, August 13, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Pharvaris Earnings Headlines

Why this biotech, up 12% since its breakout, yo-yoed on a key FDA development
July 6 at 7:23 PM  |  msn.comhttps://www.msn.com/en-us/money/general/why-this-biotech-up-12-since-its-breakout-yo-yoed-on-a-key-fda-development/ar-AA27k2hm
Why this biotech, up 14% since its breakout, is on the rise once again
July 6 at 2:18 PM  |  msn.comhttps://www.msn.com/en-us/science/biochemistry/why-this-biotech-up-14-since-its-breakout-is-on-the-rise-once-again/ar-AA27k2hm
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.tc pixel
 |  Investors Alley (Ad)
Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
July 6 at 6:50 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/06/3322293/0/en/pharvaris-announces-fda-acceptance-of-new-drug-application-for-deucrictibant-ir-for-on-demand-treatment-of-hereditary-angioedema-attacks.html
Johannes Gerardus Chri Schikan Sells 30,712 Shares of Pharvaris (NASDAQ:PHVS) Stock
July 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30876396
Cantor Fitzgerald Reaffirms Their Buy Rating on Pharvaris (PHVS)
July 1, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PHVS-Q/pressreleases/3074352/cantor-fitzgerald-reaffirms-their-buy-rating-on-pharvaris-phvs/
See More Pharvaris Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pharvaris? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pharvaris and other key companies, straight to your email.

About Pharvaris

Pharvaris (NASDAQ:PHVS) is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials. Pharvaris is also developing an on-demand version of its kallikrein inhibitor to provide patients with an acute treatment option. Both candidates represent the company’s effort to offer fully oral alternatives to current injectable therapies.

Founded in 2016 and headquartered in Leiden, the Netherlands, Pharvaris maintains a presence in the United States to support clinical development and regulatory engagement. Since completing its initial public offering on the NASDAQ in 2020, the company has expanded its research partnerships and scaled its operations to prepare for potential commercialization.

Pharvaris is led by an experienced management team with deep expertise in rare disease drug development, medicinal chemistry and clinical operations. The company’s board and advisory committees include professionals with backgrounds in immunology, hematology and regulatory affairs, guiding its strategy toward delivering innovative treatments to patients worldwide.

View Pharvaris Profile
Earnings Tools